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Background: L-Glutamate (L-Glu) is the major excitatory neurotransmitter in the CNS, and its level in cerebrospinal
fluid (CSF) is reported to be increased in neuroexcitatory diseases such as epilepsy. Since L-Glu concentration in the
CSF is reported to be lower than that in plasma, it has been proposed that some mechanisms of L-Glu clearance
from the CSF operate in the brain. The purpose of this study was to elucidate the major pathway of L-Glu elimination
from rat CSF and the transporters responsible.
Methods: Protein expression and localization of excitatory amino acid transporters were examined by
immunohistochemical analysis using specific antibodies. In vivo elimination of L-Glu from rat CSF was evaluated by
intracerebroventricular administration. An L-Glu uptake study by using primary-cultured rat ependymal cells and
isolated rat choroid plexus was performed to characterize L-Glu transport mechanisms.
Results: An immunohistochemical analysis has shown that excitatory amino acid transporter (EAAT) 1 and EAAT3,
which are D-aspartate-sensitive and kainate-insensitive L-Glu transporters, are localized on the CSF-side of rat
ependymal cells and choroid plexus epithelial cells, respectively. In contrast, the kainate-sensitive L-Glu transporter,
EAAT2, is not expressed in these cells. In vivo L-Glu elimination clearance from the rat CSF (189 μL/(min · rat)) was
23-fold higher than the CSF bulk flow rate, indicating that facilitative process(es) are involved in L-Glu elimination from
the CSF. The in vivo [3H]L-Glu elimination from the CSF was significantly inhibited by unlabeled L-Glu and D-aspartate,
but not kainate. Moreover, unlabeled L-Glu and D-aspartate inhibited [3H]L-Glu uptake by rat ependymal cells and
choroid plexus epithelial cells, whereas kainate had little effect.
Conclusion: It is suggested that EAAT1 in ependymal cells and EAAT3 in choroid plexus epithelial cells participate in
L-Glu elimination from the CSF.
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L-Glutamate (L-Glu), an acidic amino acid, is regarded
as the major excitatory synaptic neurotransmitter in the
central nervous system (CNS) [1,2]. It has been known
that L-Glu is mainly synthesized in neurons and released
to the brain interstitial fluid [1,2], from where it may
leak into the cerebrospinal fluid (CSF). In various CNS dis-
eases, such as epilepsy, multiple sclerosis and Alzheimer’s
disease, the L-Glu level in CSF, which fills the cerebral
ventricles and bathes the brain, is reported to be increased
[3,4]. Since excess accumulation of L-Glu leads to neural
excitotoxicity [1], the L-Glu level in the CNS is considered
to be strictly regulated. The L-Glu concentration in the rat
CSF has been reported to be 11.4 μM, which is 14-fold
lower than that in rat plasma [5]. Thus, it is conceivable
that some mechanisms operate to eliminate L-Glu from
the CSF and to regulate the brain/CSF L-Glu levels.
In general, it has been considered that there are three
pathways for compound elimination from the CSF/cere-
bral ventricles [6,7]: (i) convective loss of compounds
owing to CSF turnover, (ii) efflux transport across the
blood-CSF barrier (BCSFB), which consists of choroid
plexus epithelial cells (CPE cells), and (iii) uptake of the
compound into the neural cells around the cerebral ven-
tricles, such as ependymal cells. Convective loss, namely
absorption of the compound into the circulating blood
via the superior sagittal sinus, involves the passive and
constant elimination of compounds with the CSF bulk
flow rate (~2.9 μL/(min · rat)) [8]. In contrast, the other
processes involve carrier-mediated and active elimination
from the CSF. It has been reported that the transporters
at the BCSFB contribute to the facilitative efflux transport
of drugs and endogenous compounds from the CSF [9].
Regarding the carrier-mediated transport systems in epen-
dymal cells, the expression and localization of some trans-
porters, such as monocarboxylate transporters and urate
transporter 1, has been studied, although a functional
evaluation has not been fully achieved [10-12]. To con-
sider the elimination of compounds including L-Glu from
the CSF, it is important to evaluate the contribution of
these processes to L-Glu clearance from the CSF and
identify the molecule(s) responsible for this elimination.
It has been suggested that transporters which are
expressed in CPE cells and ependymal cells contribute
to L-Glu clearance from the CSF because some solute
carrier (SLC) families are reported to be involved in the
transport of L-Glu into neural cells. Excitatory amino
acid transporters (EAATs), which are referred to as system
XAG
−, mediate the uptake of L-Glu and isomers of as-
partate (Asp) [13]. To date, five distinct EAAT subtypes,
EAAT1/GLAST/Slc1a3, EAAT2/GLT-1/Slc1a2, EAAT3/
EAAC1/Slc1a1, EAAT4/Slc1a6, and EAAT5/Slc1a7, have
been identified [14]. Also transporters selectively recogniz-
ing the L-isomer of Glu and Asp, alanine-serine-cysteinetransporters 1 (ASCT1/Slc1a4) and ASCT2/Slc1a5, iso-
forms of system ASC, have been reported [14,15]. In
addition, D/L-Asp-insensitive and Na+-independent sys-
tem Xc
−, which is composed of xCT/Slc7a11 and 4F2hc/
CD98/Slc3a2, is reported to be involved in the uptake of
L-Glu and L-cystine [16-18]. The mRNA/protein expres-
sion of these transporters in ependymal cells and CPE
cells has been reported [19-23]. However, the involvement
of these transporters in the transport of L-Glu in CPE cells
and ependymal cells from the CSF remains unknown. In
particular, it has been found that the genetic deficiency of
EAAT1-3 in rodents leads to neurologic dysfunction
which is induced by excessive neuro-excitation and neuro-
toxicity [24-26]. Thus, there is a need for clarification of
the role of EAAT1-3 in the homeostasis of L-Glu level in
the brain, including L-Glu clearance from the brain/CSF.
The purpose of this study was to evaluate L-Glu elim-
ination from rat CSF and clarify the transporters respon-
sible in the cells around the cerebral ventricles. The
protein expression and localization of EAAT1-3 in rat
ependymal cells and CPE cells were investigated by
immunohistochemical analysis. To elucidate the contri-
bution of EAATs in these cells to the L-Glu transport
process, we evaluated the elimination from the CSF fol-
lowing intracerebroventricular administration, and perfor-
med transport studies using isolated rat choroid plexus
and primary-cultured rat ependymal cells.
Methods
Animals
Wistar rats (150-250 g) were purchased from Japan
SLC (Hamamatsu, Japan). They were maintained in a
controlled environment and all experiments were approved
by the Animal Care Committee, University of Toyama.
Reagents
L-Glutamic acid, [3,4-3H]- ([3H]L-Glu, 27.0 Ci/mmol) was
obtained from Moravek Biochemicals (Brea, CA, USA).
Mannitol, D-[1-14C] ([14C]D-mannitol, 55 mCi/mmol)
and butanol, n [1-14C] ([14C]n-butanol, 2 mCi/mmol)
were purchased from American Radiolabeled Chemicals
(St. Louis, MO, USA). Rabbit anti-EAAT1 antibodies
[27], which recognize EAAT1 and three kinds of splice
variants (GLAST1a, GLAST1b, and GLAST1c [22]), and
rabbit anti-EAAT2 antibodies [28], which recognize EAAT2
and do not bind to other splice variants (GLT-1b, exon
9-skipped GLT-1b, and GLT-1c [22]), were kindly gifted
from Dr. M. Watanabe, Hokkaido University, Sapporo,
Japan. All other chemicals were commercial products of
analytical grade.
Immunohistochemistry
Under deep pentobarbital anesthesia (100 mg/kg, i.p.),
adult rats (n = 4) were killed by transcardial fixation with
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(PB, pH 7.4). The brains were isolated and immersed in
4% paraformaldehyde in 0.1 M PB and then 30% sucrose
in 0.1 M PB. Frozen sections (20 μm thick) were prepared
on a cryostat (CM1900; Leica, Nussloch, Germany). The
sections were treated with 10% goat serum, and immunor-
eacted overnight with rabbit antibodies to EAAT1 (1.0 μg/
mL; [27]), EAAT2 (1.0 μg/mL; [28]), EAAT3 (2.0 μg/mL;
#EAAC11-A, Alpha Diagnostic International, San Antonio,
TX, USA) and glutamine synthetase (GS, 1.0 μg/mL; [29]).
Subsequently, they were incubated with rabbit-specific
Cy3-conjugated secondary antibodies (Jackson ImmunoRe-
search, West Grove, PA, USA) at room temperature for
2 h. Nuclei were stained by incubating with 4 μM 4′,6-
diamidino-2-phenylindole (DAPI) at room temperature
for 5 min. The images were captured using a confocal
laser scanning microscope (TCS-SP5; Leica). Fluores-
cence was detected with a confocal laser microscope
equipped with a blue diode/green diode laser system.
DAPI and Cy3 were excited sequentially using the 405
and 561 nm excitation laser wavelengths, respectively.
Images were acquired using an appropriate pinhole to
obtain 1 Airy unit. All images were acquired using con-
focal software (LAS AF, Leica), digitized at 8-bit reso-
lution into an array of 1024 × 1024 pixels.
In vivo L-Glu elimination from the CSF after
intracerebroventricular administration
The elimination of compounds after intracerebroven-
tricular administration was studied using the procedure
described previously in detail [6]. Twenty-seven rats
were anesthetized with an intraperitoneal injection of
pentobarbital (50 mg/kg), and the head was fixed with a
stereotaxic apparatus (SR-5R; Narishige, Tokyo, Japan).
A hole was drilled in the skull, 1.5 mm left and 0.5 mm
posterior to bregma, into which a needle was fixed as a
cannula for injection. [3H]L-Glu (0.4 μCi, 15 pmol) and
[14C]D-mannitol (0.01 μCi, 180 pmol) were dissolved in
10 μL extracellular cellular fluid (ECF) buffer (122 mM
NaCl, 25 mM NaHCO3, 3 mM KCl, 1.4 mM CaCl2,
1.2 mM MgSO4, 0.4 mM K2HPO4, 10 mM D-glucose,
and 10 mM HEPES, pH 7.4) and administered to the left
lateral ventricle (0.5 mm posterior and 1.5 mm lateral to
bregma; depth 4.0 mm). For inhibition studies, 50 mM
unlabeled L-Glu, 25 mM D-Asp, or 12.5 mM kainate
was administered simultaneously. Because it has been
reported that the volume of rat CSF is 250 μL [30], the
injected compounds after the intracerebroventricular
administration (10 μL) were assumed to be diluted 25-
fold. At designated times, CSF (50 μL) was withdrawn
by cisternal puncture. Levels of 3H and 14C in the CSF
and injectate were measured in a liquid scintillation
counter (AccuFLEX LSC-7400; Hitachi-Aloka Medical,
Tokyo, Japan).Since it is reported that compounds administered into
the lateral ventricles are eliminated from the CSF with
one-compartmental kinetics according to Eq. 1, the kinetic
parameters for [3H]L-Glu and [14C]D-mannitol were de-
termined from Eq. 2 using the non-linear least-squares
regression analysis program, MULTI [31]:




 100 ¼ 100
V d;CSF
 exp −kel;CSF  t
  ð2Þ
where CCSF(t), Vd,CSF and kel are the CSF concentration
at time t, the volume of distribution in the CSF and the
elimination rate constant from the CSF, respectively,
of either [3H]L-Glu or [14C]D-mannitol. “CCSF(t)/dose ×
100” in Eq. (2) expresses the percentage of the residual
concentration of compound in the CSF normalized by the
amount of injectate (% of dose/mL CSF). The apparent
elimination clearance from the CSF (CLel,CSF) was ob-
tained by multiplying kel by Vd. In the inhibition study, the
ratio of the percentage of residual concentration of [3H]L-
Glu to that of [14C]D-mannitol was evaluated in the
absence or presence of each inhibitor.
Preparation of primary-cultured rat ependymal cells
Ependymal primary cultures were prepared from the brains
of 22 newborn rats by dissociating whole brains as de-
scribed previously [32,33]. The cells were resuspended in
MEMc (minimum essential medium (MEM) supplemented
with 0.5 g/L fatty acid-free bovine serum albumin (BSA),
5 mg/L insulin, 10 mg/L transferrin), seeded on fibronec-
tin-coated culture vessels, and cultured at 37°C in humidi-
fied 5% CO2-air. Two days after the cultivation, the culture
medium was changed to MEMc containing 500 U/L
thrombin and renewed every third day. The subsequent cell
studies were performed at least 14 days after the cultivation.
To confirm prepared cells as ependymal cells, scanning
electron microscopy was performed. Primary-cultured rat
ependymal cells, which were plated onto fibronectin-coated
35 mm dish (Corning Incorporated Life Sciences, Tewksbury,
MA, USA), were prefixed with 2% glutaraldehyde in diva-
lent cation-free phosphate-buffered saline (PBS (-)) for
1 h, rinsed at least twice with PBS(-), postfixed with 1% os-
mium tetroxide in PBS(-) for 1 min at 4°C, and dehydrated
in a series of ethanol. The samples were frozen in t-butanol
at 4°C, and lyophilized. The specimens mounted on stubs
were coated with platinum and were observed with a scan-
ning electron microscope (S-4500; Hitachi, Tokyo, Japan).
Immunocytochemical analysis
Primary rat ependymal cells were cultured in fibronectin-
coated 8-well culture slides (Corning Incorporated Life
Sciences). The cultured cells were washed with PBS(-) and
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at room temperature. After treatment with 0.1% Triton X-
100 in PBS (-) for 10 min, the cells were blocked with 10%
goat serum and then incubated overnight at 4°C with poly-
clonal rabbit anti-EAAT1 antibody (1 μg/mL; [27]) in 0.1%
Triton X-100/PBS(-). Subsequently, the cells were incu-
bated with Cy3-conjugated anti-rabbit IgG (1:200; Jackson
ImmunoResearch). Nuclei were stained with 4 μM DAPI.
The method for capturing images is the same as that de-
scribed in the “Immunohistochemical analysis” subsection.
[3H]L-Glu uptake by primary-cultured rat ependymal cells
Primary-cultured rat ependymal cells on fibronectin-
coated 24-well plates (Corning Incorporated Life Sci-
ences) were washed with ECF buffer, and incubated with
0.5 μCi/mL (19 nM) [3H]L-Glu at 37°C for 10 min in
the absence or presence of inhibitors. After the assay,
the cells were rinsed 3 times with ice-cold ECF buffer,
lysed in 1 M NaOH, and neutralized with 1 M HCl. The
radioactivity derived from [3H]L-Glu was measured in a
liquid scintillation counter (AccuFLEX LSC-7400). A
DC protein assay kit (Bio-Rad, Hercules, CA, USA) with
BSA as a standard was employed to quantify the amount
of cellular protein. The cellular uptake of [3H]L-Glu was
evaluated as the cell/medium ratio according to Eq. 3.
Cell=medium ratio μL=mg proteinð Þ
¼
3H‐Radioactivity per cell protein dpm=mg proteinð Þ
3H‐Radioactivity concentration in medium dpm=μLð Þ
ð3Þ
L-Glu uptake using freshly isolated rat choroid plexus
The uptake of [3H]L-Glu by rat choroid plexus was exam-
ined using the centrifugal filtration method described
previously with minor modifications [34]. Thirty-one rats
were decapitated, and then the choroid plexus was iso-
lated from the lateral ventricles and pre-incubated at 37°C
for 1 min in 100 μL ECF buffer. To initiate [3H]L-Glu up-
take, pre-incubated choroid plexus was transferred to ECF
buffer containing [3H]L-Glu (0.2 μCi/sample) and [14C]n-
butanol (0.02 μCi/sample) in the absence (control) or
presence of inhibitors. [14C]n-Butanol was used as a
marker of the water space of the rat choroid plexus. The
final concentrations of [3H]L-Glu and [14C]n-butanol were
selected as 74 nM and 100 μM, respectively. The ra-
dioactivity of 3H and 14C was determined using a liquid
scintillation counter (AccuFLEX LSC-7400). The tissue/
medium concentration ratio was calculated from Eq. 4.Tissue=medium ratio
μL=μL choroid plexusð Þ ¼
Amount of 3H½ L‐Glu accumulated
3H½ L‐Glu concen
Amount of 14C½ n‐butanol accumula
14C½ n‐Butanol concData analysis
The kinetic parameters, such as Vd,CSF, kel, and CLel,CSF,
determined by the least-squares regression analysis are
presented as the mean ± SD. Other data represent the
mean ± SEM. Statistical significance of differences be-
tween the means was determined by using the unpaired
two-tailed Student’s t-test for two groups and one-way
analysis of variance followed by Dunnett’s test for more
than two groups. A value of p < 0.05 was accepted as
statistically significant.Results
Immunohistochemical analysis of EAAT1, EAAT2, EAAT3
and GS expression in the cells around the rat lateral
ventricle
The expression and localization of EAAT1-3 proteins
in the cells around the lateral ventricle were exam-
ined by immunohistochemical analysis using specific
antibodies for these transporters. Immunoreactivities
derived from EAAT1, EAAT2, and EAAT3 were detected
in neural cells of the brain parenchyma (red, Figure 1A-C).
Immunostaining of EAAT1 (red, Figure 1A) was observed
in the layer lining the lateral ventricles (arrow heads),
whereas that of EAAT2 and EAAT3 (red, Figure 1B and C)
was not detected in this layer. At higher magnification, the
EAAT1 immunoreactivities were detected on the CSF side
of the cells (arrow heads, Figure 1A2-A3), indicating that
EAAT1 is localized on the apical membrane of ependymal
cells. In contrast, the EAAT2 immunoreactivities were not
detected on the CSF side of the cells (arrow heads) but
on the brain side around the nucleus (Figure 1B2-B3).
This result suggests that EAAT2 may be localized on
the basal membrane of ependymal cells or on the
end-feet of neural cells, such as astrocytes. L-Glu is
metabolized to L-glutamine (L-Gln), an inactive sub-
stance, via glutamine synthetase (GS) [35]. The GS
antibody resulted in the labeling of intracellular compart-
ments of the ependymal cells (arrow heads, Figure 1D2-
D3).
In rat CPE cells, EAAT3 immunoreactivities were very
high (arrows) compared with ependymal cells (arrow
heads, Figure 1C1). In contrast, immunostaining of
EAAT1 and EAAT2 was not observed in CPE cells (ar-
rows, Figure 1A1 and B1). At a high magnification, the
EAAT3 immunoreactivities were detected on the CSF
side/apical membrane of the CPE cells (Figure 1C2-C4,
arrows).in the choroid plexus dpm=the choroid plexusð Þ
tration in the medium dpm=μLð Þ
ted in the choroid plexus dpm=the choroid plexusð Þ
entration in the medium dpm=μLð Þ
ð4Þ
Figure 1 Immunohistochemical localization of EAAT1, EAAT2, EAAT3 and GS in neural cells around the rat lateral ventricle. Frozen sagittal
sections from 6-week-old rats were stained with anti-EAAT1 (A), anti-EAAT2 (B), anti-EAAT3 (C), or anti-GS (D) antibodies (red). The nucleus was
visualized by incubating with DAPI (blue). A, EAAT1 immunoreactivity (red) was observed in the cells lining the lateral ventricle (LV) (arrow heads,
A1), but not in the choroid plexus epithelial cells (CPx, arrows). At high magnification (A2-A3), EAAT1 was localized on the apical membrane
(arrow heads) of the ependymal cells (Ep). B, EAAT2 immunoreactivity (red) was not observed in the cells lining the LV (arrow heads, B1) and
choroid plexus epithelial cells (arrows, B1) although it was detected in the parenchymal cells in the brain. At high magnification (B2-B3), EAAT2
was not localized on the apical membrane (arrow heads) of the ependymal cells. C, EAAT3 immunoreactivity (red) was strongly detected in the
choroid plexus epithelial cells (arrows) in the brain compared with the ependymal cells (arrow heads). At high magnification (C2-C4), EAAT3 was
localized on the apical membrane (arrows) of the choroid plexus epithelial cells. D, GS immunoreactivity (red) was observed in the cells lining the
LV (arrow heads, D1) as well as the parenchymal cells in the brain. At high magnification (D2-D3), GS was expressed in the ependymal cells (arrow
heads). Scale bar: 50 μm (A1, B1, C1, D1), 2 μm (A2-A3, B2-B3, D2-D3), 5 μm (C2-C4).
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intracerebroventricular administration
Figure 2A shows the residual CSF concentration of
[3H]L-Glu and [14C]D-mannitol after intracerebroven-
tricular administration as a function of time. [3H]L-Glu
was eliminated from the CSF with an elimination rate
constant (kel,CSF) of 0.208 ± 0.032 min
−1. This value was
4.5-fold greater than that of [14C]D-mannitol (0.0460 ±
0.0266 min−1), which is a reference compound for CSF
turnover and diffusion into the brain interstitial space
through the ependymal layer. The volumes of distribution
in the CSF (Vd,CSF) of [
3H]L-Glu and [14C]D-mannitol
were found to be 894 ± 131 μL/rat and 193 ± 131 μL/rat,
respectively. The apparent elimination clearance (CLel,CSF)
of [3H]L-Glu from the CSF (189 ± 34 μL/(min · rat)) was
20.9-fold greater than that of [14C]D-mannitol (8.89 ±
5.38 μL/(min · rat)). The elimination clearance of [14C]D-
mannitol was in agreement with that in a previous report[6], and close to the CSF bulk flow rate (2.9 μL/(min · rat))
which was obtained by Suzuki et al. [8].
Following co-administration of unlabeled L-Glu (50 mM)
into rat lateral ventricle, the 3H/14C ratio of the residual
concentration in the CSF at 5 min was 8.4-fold greater than
that in the control (Figure 2B). In addition, the simultan-
eous injection of 25 mM D-Asp with [3H]L-Glu resulted
in a 3.7-fold increase in this ratio compared with that
in the control, whereas co-administration of 12.5 mM
kainate with [3H]L-Glu had little effect (Figure 2B).
These results indicate that [3H]L-Glu elimination from rat
CSF is inhibited in the co-presence of unlabeled L-Glu
and D-Asp but not kainate.
Expression of EAAT1 protein in primary-cultured rat
ependymal cells
To investigate the existence of D-Asp-sensitive and
kainate-insensitive L-Glu transport systems in ependymal
Figure 2 In vivo elimination of [3H]L-Glu from rat CSF. A. Residual concentration in rat CSF versus time profiles of [3H]L-Glu (closed circle) and
[14C]D-mannitol (open square) after intracerebroventricular administration. The solution (10 μL) containing [3H]L-Glu (1.5 μM) and [14C]D-mannitol
(18 μM) was administered into the rat lateral ventricle. The solid line was obtained using non-linear least-squares regression analysis. Each point
represents the mean ± SEM (n = 3-4). B. Inhibition of [3H]L-Glu elimination from the CSF by simultaneous injection of unlabeled L-Glu (50 mM),
D-Asp (25 mM), and kainite (12.5 mM). The concentrations in rat CSF of L-Glu, D-Asp, and kainate were estimated to be 2 mM, 1 mM, and
0.5 mM, respectively. The values, determined 5 min after intracerebroventricular administration, are expressed as the ratio of 3H/14C in the CSF
divided by the same ratio in the injectate. Each column represents the mean ± SEM (n = 3-6). **p < 0.01, significantly different from the control.
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sensitive and kainate-insensitive transporter, in primary-
cultured rat ependymal cells, was examined. The cilia-like
morphology was observed in 2-week-old ependymal cul-
ture by scanning electron microscopy. This is illustrated
in (Additional file 1: Figure S1, Inspection of primary-
cultured rat ependymal cells by scanning electron micros-
copy), indicating the validity of primary-cultured rat epen-
dymal cells for this study. In immunocytochemical studies
using anti-EAAT1 antibodies, immunostaining of EAAT1Figure 3 Immunostaining of EAAT1 in primary-cultured rat ependymal cel
with anti-EAAT1 antibodies (red, A and B). Nuclei were stained with DAPI (was observed in primary-cultured cells (Figure 3). The
EAAT1 immunoreactivities were found to be high not
only in the nucleus (Figure 3A-C) but also in the plasma
membrane of the cell (Figure 3A and B).
L-Glu uptake by primary-cultured rat ependymal cells
To examine the L-Glu transport mechanism(s) in epen-
dymal cells, the effect of compounds on [3H]L-Glu up-
take by primary-cultured rat ependymal cells was tested.
[3H]L-Glu uptake by primary-cultured rat ependymalls. Two-week-old primary-cultured rat ependymal cells were incubated
A and C). Scale bar: 5 μm.
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presence of unlabeled L-Glu and D-Asp, respectively
(Figure 4). On the other hand, 0.5 mM kainate had little
effect on [3H]L-Glu uptake by primary-cultured rat
ependymal cells (Figure 4).
Characteristics of L-Glu uptake by isolated rat choroid
plexus
To examine whether L-Glu was eliminated from the
CSF via the BCSFB, a [3H]L-Glu uptake study using
isolated rat choroid plexus was performed. [3H]L-Glu
uptake by isolated rat choroid plexus exhibited a time-
dependent increase linearly for up to 5 min incubation
with an initial uptake rate of 0.249 ± 0.047 μL/(min · μL
choroid plexus) (Figure 5A). Since the volume of total
choroid plexus has been reported to be 6 μL/rat [6], the
elimination clearance of L-Glu from rat CSF across the
BCSFB was estimated to be 1.49 ± 0.28 μL/(min · rat) by
multiplying the initial uptake rate of [3H]L-Glu by the
volume of total choroid plexus. Figure 5B shows the
effect of compounds on [3H]L-Glu uptake by isolated rat
choroid plexus. Unlabeled L-Glu (1 mM) significantly
inhibited [3H]L-Glu uptake by isolated rat choroid
plexus by 67%, indicating the involvement of carrier-
mediated process(es) in L-Glu transport across the apical
membrane of the BCSFB. [3H]L-Glu uptake by isolated
rat choroid plexus was significantly inhibited by 43% in
the presence of 1 mM D-Asp. In contrast, [3H]L-GluFigure 4 Effect of compounds on [3H]L-Glu uptake by primary-
cultured rat ependymal cells. [3H]L-Glu (0.5 μCi/mL, 19 nM) uptake by
2-week-old primary-cultured rat ependymal cells was performed at
37°C for 10 min in the absence (control) or presence of unlabeled
L-Glu (1 mM), L-Asp (1 mM), or kainate (0.5 mM). Each column
represents the mean ± SEM (n = 3-6). *p < 0.05, **p < 0.01, significantly
different from the control.uptake was not significantly altered in the presence of
0.5 mM kainate, which selectively inhibits EAAT2, or
0.25 mM L-cystine, which is a substrate of xCT.
Discussion
In the present study, it was found that EAAT1 and
EAAT3 were localized on the CSF side of ependymal
cells and CPE cells, respectively (Figure 1). Based on
these findings, the involvement of these L-Glu trans-
porters in the elimination of L-Glu from the CSF was in-
vestigated by evaluating in vivo L-Glu elimination from
the CSF (Figure 2) and transport studies using primary-
cultured rat ependymal cells (Figure 4) and isolated rat
choroid plexus (Figure 5).
[3H]L-Glu injected into the rat lateral ventricle was
rapidly eliminated from the CSF (CLCSF,eff = 189 μL/
(min · rat)) compared with [14C]D-mannitol (CLCSF,eff =
8.89 μL/(min · rat); Figure 2A), and this [3H]L-Glu elim-
ination was inhibited by the simultaneous injection of
unlabeled 50 mM L-Glu (Figure 2B). Because it has been
reported that the volume of rat CSF is 250 μL [30], the
injected compounds after the intracerebroventricular
administration (10 μL) would have been diluted 25-fold.
Based on this assumption, the concentration of un-
labeled L-Glu after the simultaneous injection was esti-
mated to be 2 mM, which is high enough to inhibit
EAATs, ASCTs, and xCT [36-42]. These results suggest
the involvement of a saturable process in the elimination
of L-Glu from the CSF. D-Asp is reported to be a sub-
strate of EAATs with Km of less than 100 μM [43,44],
and not a substrate or an inhibitor of ASCTs and xCT
[15,17]. D-Asp (25 mM; estimated CSF concentration =
1 mM) co-administration inhibited [3H]L-Glu elimin-
ation from the CSF. This result indicates that EAATs are
involved in the in vivo L-Glu elimination from the CSF.
In contrast, co-administration of kainate (12.5 mM) did
not significantly alter [3H]L-Glu elimination. Under this
condition, the kainate concentration in the CSF was esti-
mated to be 500 μM. It has been reported that kainate
inhibits EAAT2 with a Ki of 59 μM, but not EAAT1 and
EAAT3 at concentrations of 1 mM [43]. Taking these
pieces of evidence into consideration, it is suggested that
EAAT1 and EAAT3 play a role in the in vivo elimination
of L-Glu from the CSF.
Our in vitro transport studies imply that EAATs are
involved in the uptake of L-Glu into CPE and ependymal
cells from the CSF via carrier-mediated mechanisms.
EAAT1, EAAT3, and xCT have been reported to be
expressed in ependymal cells although their localization
on ependymal cells has not been fully evaluated [22,19].
From our immunohistochemical study using rat brain sec-
tions (Figure 1A-C), we found that EAAT1 was strongly
expressed in ependymal cells relative to CPE cells, and
localized on the apical membrane (i.e. CSF side) of the
Figure 5 Characteristics of [3H]L-Glu transport at the blood-cerebrospinal fluid barrier. Isolated rat choroid plexus was incubated at 37°C with
[3H]L-Glu (74 nM) and [14C]n-butanol (100 μM), which was used to determine the cell volume of the choroid plexus. A. Time-course of [3H]L-Glu
uptake by isolated rat choroid plexus. Each point represents the mean ± SEM (n = 3-4). B. Effect of compounds on [3H]L-Glu uptake by isolated rat
choroid plexus. Choroid plexus was incubated with [3H]L-Glu for 5 min in the absence (control) or presence of unlabeled L-Glu (1 mM), D-Asp
(1 mM), kainate (0.5 mM), or L-cystine (0.25 mM). Each column represents the mean ± SEM (n = 3-4). *p < 0.05, **p < 0.01, significantly different
from the control.
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in this study also recognize splice variants of EAAT1, such
as GLAST1a, GLAST1b, and GLAST1c. Lee et al. have
indicated that GLAST1a and GLAST1c are strongly
expressed on the apical membrane of the choroid plexus
epithelial cells [22]. Taking these points into consideration,
we suggest that EAAT1 and/or GLAST1b are expressed
in ependymal cells, and the protein expression level of
these molecules on the apical membrane of epen-
dymal cells is greater than that of EAAT1/GLAST and
GLAST1a-1c in choroid plexus epithelial cells. In contrast,
the protein expression of EAAT2 and EAAT3 in rat epen-
dymal cells was lower than that in brain parenchymal cells
and CPE cells, respectively (Figure 1B and C). It has been
reported that GLT-1b and exon 9-skipped GLT-1b are
localized on the apical membrane of choroid plexus epi-
thelial cells [22], implying that these transporters could be
involved in L-Glu uptake by choroid plexus epithelial cells.
The uptake of [3H]L-Glu by primary-cultured rat epen-
dymal cells, which express EAAT1 protein (Figure 3), was
significantly inhibited by unlabeled L-Glu (Figure 4),
suggesting the presence of a carrier-mediated transport
system for L-Glu in ependymal cells. Moreover, this L-
Glu uptake was significantly inhibited in the presence of
D-Asp, a substrate of EAAT1-5 and not a substrate/in-
hibitor of ASCT1-2 and xCT [15,17]. On the other
hand, the uptake was not significantly altered in the
presence of kainate, which is an inhibitor of EAAT2/
GLT-1 (Figure 4). These results suggest a minor contri-
bution of EAAT2, ASCT1-2, and xCT to L-Glu uptake
by ependymal cells. Although a selective inhibitoryeffect of EAAT1 and GLAST1b on L-Glu uptake by
ependymal cells has not been elucidated, it is implied
that EAAT1 is, at least in part, involved in the L-Glu up-
take from the CSF into ependymal cells.
Regarding the L-Glu transport in rat CPE cells, we
have already reported that L-Glu is taken up into a
conditionally-immortalized rat CPE cell line [45], but
the contribution to the L-Glu transport from the CSF to
the CPE cells has not yet been determined. Our immu-
nohistochemical studies revealed that EAAT3 was local-
ized on the apical membrane of choroid plexus epithelial
cells (Figure 1C), whereas EAAT1 and EAAT2 were not
strongly expressed in CPE cells compared with epen-
dymal cells and/or brain parenchymal cells (Figure 1A
and B). It has been reported that two splice variants of
EAAT1 (GLAST1a and GLAST1c) and two splice vari-
ants of EAAT2 (GLT-1b and exon 9-skipped GLT-1b)
are localized on the apical membrane of choroid plexus
epithelial cells [22]. Because anti-EAAT1 antibodies also
recognize GLAST1a and GLAST1c, the protein expres-
sion level of these splice variants in choroid plexus epithe-
lial cells could be low compared with that in ependymal
cells. As for other L-Glu transporters, it has been reported
that xCT proteins are localized on the apical membrane of
rat CPE cells, and mRNAs of ASCT1 and ASCT2 are
expressed in the rat isolated choroid plexus [20,21,44,46].
[3H]L-Glu uptake by isolated rat choroid plexus was
inhibited by unlabeled L-Glu and D-Asp, but not kainate
(a selective inhibitor of EAAT2) and L-cystine (a substrate
of xCT, Km = 48 μM) (Figure 5B) [16,43]. In addition,
ASCTs and xCT are reported to be D-Asp-insensitive
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exon 9-skipped GLT-1b, ASCTs, and xCT play a minor
role in L-Glu transport at the apical membrane of choroid
plexus epithelial cells although ASCTs and xCT are
expressed in choroid plexus epithelial cells. Taking these
points into consideration, it is indicated that EAAT3 is in-
volved in L-Glu uptake by isolated rat choroid plexus. To
elucidate the contribution of EAAT3 to L-Glu transport in
rat CPE cells, further studies on selective EAAT3 inhib-
ition are needed. Nevertheless, our study suggests that
EAAT3 participates in the transport of L-Glu from the
CSF to CPE cells.
From the kinetic analyses of in vivo L-Glu elimination
from CSF and the in vitro L-Glu uptake study by isolated
rat choroid plexus, it does not seem that the convective
loss due to turnover of the CSF and efflux transport
across the BCSFB are major pathways for the clearance
of L-Glu from the CSF. As the elimination clearance of
D-mannitol from the CSF was found to be 8.89 μL/
(min · rat) (Figure 2A), only 5% of the total L-Glu elimin-
ation from the CSF (189 μL/(min · rat)) would reflect the
CSF bulk flow and diffusion into the brain interstitial
space. In addition, the BCSFB-mediated elimination
clearance of L-Glu from the CSF was estimated to be
1.49 μL/(min · rat) from the initial uptake rate of L-Glu
by the isolated rat choroid plexus (Figure 5A). This value
is 1% of the total L-Glu elimination from the CSF, and
extremely low compared with the estimated efflux clear-
ance of compounds, such as benzylpenicillin and PGE2,
which shows facilitative elimination via the transporters
at the BCSFB [6,47,48]. Thus, it appears that the CSF
turnover and the BCSFB-mediated L-Glu efflux trans-
port from the CSF contribute to only ~5.5% of L-Glu
elimination from the CSF. Other routes for L-Glu elim-
ination from the CSF, the remaining ~95%, have to be
considered. Uptake of L-Glu into the neural cells which
face the CSF and express some L-Glu transporters is
thought to be most likely. It has been reported that the pro-
cesses of astrocytes, which show L-Glu uptake via EAAT1
and EAAT2, are assembled next to the CSF [49,50]. In
addition, our study reveals L-Glu uptake by ependymal cells
via EAATs (Figure 4) and the localization of EAAT1 on the
CSF side of the ependymal cells (Figure 1A). Harandi et al.
have reported that [3H]L-Glu-derived signals were strongly
detected on the layer of ependymal cells after intracerebro-
ventricular administration of [3H]L-Glu [51]. Although the
surface area of the ependymal cells has reported to be
2 cm2 [52], which is 37.5-fold lower than that of choroid
plexus epithelial cells (75 cm2) [53], it is suggested that
EAAT1-mediated L-Glu uptake into ependymal cells con-
tributes, at least in part, to the major pathway (~95%) of
L-Glu elimination from the CSF.
Our immunohistochemical study revealed the expres-
sion of GS in ependymal cells (Figure 1D). This resultimplies that ependymal cells are involved not only in the
elimination of L-Glu from CSF but also in the supply of
L-glutamine to the brain through that L-Glu uptake. It
has been reported that EAAT1 deficiency is linked to
epileptic syndrome [54]. In epileptic patients, the ratio
of L-glutamine/L-Glu in the cerebral cortex and hippo-
campus is reported to be decreased [55]. Therefore, it is
possible that transport of EAAT1-mediated L-Glu from
the CSF and then GS-mediated conversion to L-glutamine
play a role in preventing epileptic seizures, and this should
be taken into consideration as therapeutic targets for the
treatment of epilepsy.Conclusions
Ependymal cells play an important role in the elimination
of L-Glu from the CSF. Moreover, EAAT1 on the apical
membrane of ependymal cells takes part in the removal of
L-Glu from the CSF, thereby maintaining a low L-Glu
concentration in the CSF compared with that in plasma.
Our findings provide a novel insight into the role of the
ependymal cells in the homeostasis of the cerebral L-Glu
level and may help us understand the pathogenesis of neu-
roexcitatory diseases.Additional file
Additional file 1: Inspection of primary-cultured rat ependymal
cells by scanning electron microscopy.Abbreviations
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